Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Celgene Cp Cvr (CELGZ)

Celgene Cp Cvr (CELGZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.40 +17.48%
on 11/20/19
0.53 -11.34%
on 10/31/19
unch (-0.02%)
since 10/29/19
3-Month
0.40 +17.48%
on 11/20/19
1.24 -62.10%
on 09/26/19
-0.08 (-14.58%)
since 08/29/19
52-Week
0.35 +34.26%
on 12/28/18
1.65 -71.52%
on 03/12/19
-0.42 (-47.20%)
since 11/28/18

Most Recent Stories

More News
Worldwide CAR T Cell Therapy Market 2020 - IPO/Investment/Funding/Partnership in CAR-T Cell Therapy Market

, /PRNewswire/ -- The report has been added to offering.

CELGZ : 0.47 (+2.15%)
CYAD : 10.11 (+4.01%)
GILD : 70.88 (-1.18%)
JUNO : 86.96 (+0.10%)
KITE : 179.99 (+0.11%)
NVS : 84.15 (+0.60%)
GreenStar Biosciences Signs Definitive Agreement to Acquire 100% of Eleusian Biosciences Corp.

Vancouver, British Columbia--(Newsfile Corp. - July 21, 2020) -  GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) ("" or the "") is pleased to announce, further to its press release dated June...

CELGZ : 0.47 (+2.15%)
GTSIF : 0.0735 (+2.23%)
SCYB.VN : 3.490 (-5.93%)
GSTR.CN : 0.100 (-4.76%)
Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization

Antengene Corporation, a leading innovative hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and best-in-class therapies,...

BMY : 59.47 (+0.63%)
CELGZ : 0.47 (+2.15%)
BILI : 45.19 (-1.82%)
ZLAB : 80.00 (-0.31%)
SDGR : 72.61 (-1.57%)
Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D. as Chief Medical Officer (CMO) and Executive Vice President

, /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced...

CELGZ : 0.47 (+2.15%)
CTXR : 1.2900 (+2.38%)
Psoriasis Treatment Market to Cross USD 40.58 Billion by 2027; Increasing Prevalence of Psoriatic Arthritis to Aid Growth, says Fortune Business Insights(TM)

The global psoriasis treatment market size is projected to reach USD 40.58 billion by the end of 2027. Increasing focus on development of biologics for psoriasis treatment will aid the growth of the overall...

AMGN : 243.59 (-1.52%)
CELGZ : 0.47 (+2.15%)
LLY : 154.85 (+1.32%)
NVS : 84.15 (+0.60%)
PFE : 38.39 (+0.10%)
Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (ECS),...

CELGZ : 0.47 (+2.15%)
ENTA : 47.69 (+1.36%)
NVS : 84.15 (+0.60%)
CRBP : 6.86 (+1.03%)
Global CAR T Cell Therapy Market to 2026 - by Regions, Targeted Antigens, Clinical Trials/Study & Companies - ResearchAndMarkets.com

The "CAR T Cell Therapy Market Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies" report has been added to ResearchAndMarkets.com's offering.

CELGZ : 0.47 (+2.15%)
CYAD : 10.11 (+4.01%)
GILD : 70.88 (-1.18%)
JUNO : 86.96 (+0.10%)
KITE : 179.99 (+0.11%)
NVS : 84.15 (+0.60%)
Amgen Is Supporting Advancement Of AMG 634 For Global Health Diseases In Developing Countries

, /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced it is supporting the further study of AMG 634, a phosphodiesterase type 4 (PDE4) inhibitor, for the treatment of tuberculosis (TB) and erythema nodosum...

CELGZ : 0.47 (+2.15%)
AMGN : 243.59 (-1.52%)
Leukemia Therapeutics Markets, 2015-2025 - Size by Value & Volume, Trends & Developments, Competitive Landscape

, /PRNewswire/ -- The report has been added to offering.

BMY : 59.47 (+0.63%)
CELGZ : 0.47 (+2.15%)
LLY : 154.85 (+1.32%)
INCY : 99.95 (-1.81%)
MRK : 81.67 (-1.05%)
PKI : 120.82 (-0.78%)
Greenstar Biosciences Signs Agreement to Acquire 100% of Eleusian Biosciences Corp.

Vancouver, British Columbia--(Newsfile Corp. - June 16, 2020) - GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) ("" or the ""), is pleased to announce that it has signed a non-binding letter...

CELGZ : 0.47 (+2.15%)
GTSIF : 0.0735 (+2.23%)
SCYB.VN : 3.490 (-5.93%)
GSTR.CN : 0.100 (-4.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CELGZ with:

Business Summary

N/A

See More

Key Turning Points

2nd Resistance Point 0.50
1st Resistance Point 0.49
Last Price 0.47
1st Support Level 0.45
2nd Support Level 0.42

See More

52-Week High 1.65
Fibonacci 61.8% 1.15
Fibonacci 50% 1.00
Fibonacci 38.2% 0.85
Last Price 0.47
52-Week Low 0.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar